[Pharmacogenetics for patient care in France: A discipline that evolves!]

La pharmacogénétique au service du soin en France : une discipline qui évolue !
Drug label Dépistage pré-thérapeutique Ethics Next generation sequençing Pharmacogenetics Pharmacogénétique Pretherapeutic screening Réseau national de pharmacogénétique Résumé des caractéristiques du produit Séquençage à haut débit Éthique

Journal

Therapie
ISSN: 1958-5578
Titre abrégé: Therapie
Pays: France
ID NLM: 0420544

Informations de publication

Date de publication:
Historique:
received: 15 05 2019
revised: 12 08 2019
accepted: 24 09 2019
pubmed: 27 11 2019
medline: 18 9 2021
entrez: 27 11 2019
Statut: ppublish

Résumé

Pharmacogenetics, which concepts are known for a long time, is entering a new period at least as far as its practical applications for patients are concerned. In recent years there have been more and more initiatives to promote widespread dissemination, and health authorities are increasingly incorporating these concepts into drug labels. In France, the national network of pharmacogenetics (RNPGx) works to promote these activities, both with health actors (biologists, clinicians) and health authorities. This article reviews the current situation in France and the milestones of the year 2018. It highlights recent advances in this field, in terms of currently recommended analyses, sharing of information or technological developments, and the prospects for future developments in the near future from targeted pharmacogenetics to eventually preemptive approaches.

Identifiants

pubmed: 31767126
pii: S0040-5957(19)30154-4
doi: 10.1016/j.therap.2019.09.006
pii:
doi:

Types de publication

Journal Article Review

Langues

fre

Sous-ensembles de citation

IM

Pagination

459-470

Informations de copyright

Copyright © 2019 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved.

Auteurs

Chantal Barin-Le Guellec (C)

Inserm U1248, laboratoire de biochimie et biologie moléculaire, université de Tours, CHU de tours, 2, boulevard Tonnellé, 37044 Tours cedex, France. Electronic address: chantal.barin-leguellec@univ-tours.fr.

Nicolas Picard (N)

Inserm U1248, service de pharmacologie et toxicologie, université de Limoges, CHU de Limoges, 87042 Limoges, France.

Hugo Alarcan (H)

Inserm U1248, laboratoire de biochimie et biologie moléculaire, université de Tours, CHU de tours, 2, boulevard Tonnellé, 37044 Tours cedex, France.

Melody Barreau (M)

Inserm U1107, Service de pharmacologie, université d'Auvergne, CHU de Clermont-Ferrand, 63001 Clermont-Ferrand, France.

Laurent Becquemont (L)

CESP/Inserm U1018, Centre de recherche clinique, hôpital Bicêtre, université Paris Sud, 94275 Le Kremlin-Bicêtre, France.

Sylvie Quaranta (S)

Laboratoire de pharmacocinétique et toxicologie, CHU Timone, 13005 Marseille, France.

Jean-Christophe Boyer (JC)

Laboratoire de biochimie et biologie moléculaire, CHU Carémeau, 30000 Nîmes, France.

Marie-Anne Loriot (MA)

Inserm U1144, service de biochimie, hôpital européen Georges-Pompidou, université Paris Descartes, 75015 Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH